<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918680</url>
  </required_header>
  <id_info>
    <org_study_id>EcoFit® Post-market Study</org_study_id>
    <nct_id>NCT04918680</nct_id>
  </id_info>
  <brief_title>Prospective Post-market Study Examining the Effectiveness of the EcoFit®</brief_title>
  <official_title>Prospective Post-market Study Examining the Effectiveness of the EcoFit® Total Hip System With Implacross® E Polyethylene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Implantcast North America, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Implantcast North America, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the EcoFit Hip with&#xD;
      implacross E polyethylene for total hip replacement surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the performance and success rate of the EcoFit Total Hip System.&#xD;
      Survivorship and clinical outcomes will help determine implant success 36 months as defined&#xD;
      by specific scoring systems and compared to other published data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 21, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate the overall survivorship of the devices. Observed product-related complications and revisions are recorded and documented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pre to post-op change in the Harris Hip Score</measure>
    <time_frame>Pre-op, 6 months, 12 months, 24 months, 36 months</time_frame>
    <description>The Harris Hip Score tracks pain, function/gait, performance in functional activities, and range of motion as interpreted by the surgeon. The responses determine a score which can be compared in different intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pre to post-op change in the WOMAC Score</measure>
    <time_frame>Pre-op, 6 months, 12 months, 24 months, 36 months</time_frame>
    <description>The Western Ontario McMaster Arthritis Index, a questionnaire completed by the patient, tracks pain, stiffness, and difficulty with daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related complications</measure>
    <time_frame>Through completion of study, an average of 3.5 years</time_frame>
    <description>Detect any device related complications via the adverse events reporting</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Degenerative Joint Disease</condition>
  <condition>Femoral Fracture</condition>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Traumatic Arthritis</condition>
  <arm_group>
    <arm_group_label>EcoFit® Total Hip System with implacross® E Polyethylene</arm_group_label>
    <description>Subjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EcoFit® Total Hip System with implacross® E Polyethylene</intervention_name>
    <description>The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.</description>
    <arm_group_label>EcoFit® Total Hip System with implacross® E Polyethylene</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PIs will recruit from their patient population; patients already intending to undergo a&#xD;
        total hip replacement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be a candidate for a total primary hip replacement.&#xD;
&#xD;
          -  Subject must have degenerative joint disease, including osteoarthritis or traumatic&#xD;
             arthritis, OR a femoral fracture which can be treated by a primary hip replacement and&#xD;
             no other hardware&#xD;
&#xD;
          -  Subject has a BMI of 40.00 kg/m2 or less at the time of enrollment&#xD;
&#xD;
          -  Subject is likely to be available for evaluation for the duration of the study&#xD;
&#xD;
          -  Subject is able and willing to sign the informed consent and follow study procedures&#xD;
&#xD;
          -  Subject is not pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has had a prior hip replacement in the subject hip&#xD;
&#xD;
          -  Subject has an active cancer or is a survivor for &lt;5 years except for squamous cell or&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  Subject has a chronic disease(s) where, in the opinion of the investigator, the&#xD;
             disease will interfere with the patient's ability to follow the protocol&#xD;
&#xD;
          -  Subject is currently a documented substance abuser (alcohol or other addictions)&#xD;
&#xD;
          -  Subject has an infection, or history of infection (within the last 3 months), acute or&#xD;
             chronic, local or systemic&#xD;
&#xD;
          -  Subject has a history of muscular, neurological or vascular deficiencies which&#xD;
             compromise the affected extremity&#xD;
&#xD;
          -  Subject has a BMI &gt; 40.00 kg/m2&#xD;
&#xD;
          -  Subject has a mental condition that may interfere with the subject's ability to give&#xD;
             an informed consent or willingness to fulfill the study requirements (i.e., severe&#xD;
             mental retardation such that the Subject cannot understand the informed consent&#xD;
             process, global dementia, prior strokes that interfere with the Subject's cognitive&#xD;
             abilities, senile dementia, and Alzheimer's Disease)&#xD;
&#xD;
          -  Subject is a prisoner&#xD;
&#xD;
          -  Subject is pregnant&#xD;
&#xD;
          -  Subject has known materials sensitivity (to metals)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

